Evidence map›Paper›PMID 37074571›Full record

ArticleInvestigational new drugs2023

A dose escalation/expansion study evaluating dose, safety, and efficacy of the novel tyrosine kinase inhibitor surufatinib, which inhibits VEGFR 1, 2, & 3, FGFR 1, and CSF1R, in US patients with neuroendocrine tumors.

Arvind Dasari, Erika P Hamilton, Gerald S Falchook, Judy S Wang, Daneng Li, Max W Sung, Caly Chien, Shivani Nanda, Christopher Tucci, Marjo Hahka-Kemppinen and 1 more

Registry-linked trialOpen access · hybridAbstract read
In one paragraph

Article in Investigational new drugs, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02549937 (A Multi-Center, Open-Label, Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Surufatinib), which is not on this map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02549937 phase1 / phase2completednot on this map

A Multi-Center, Open-Label, Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Surufatinib (HMPL-012), Previously Named Sulfatinib in Advanced Solid Tumors

TypeinterventionalSponsorHutchmedRan2015 to 2023Enrolled130ConditionsTumorsArmssurufatinib
3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Observational
  4. Review
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 1 country.

Arvind DasariMD Anderson Cancer Center, Houston, TX, USA. ADasari@mdanderson.org.
Erika P HamiltonSarah Cannon Research Institute/Tennessee Oncology, Nashville, TN, USA.
Gerald S FalchookSarah Cannon Research Institute at HealthONE, Denver, CO, USA.
Judy S WangFlorida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL, USA.
Daneng LiCity of Hope Comprehensive Cancer Center and Beckman Research Institute, Duarte, CA, USA.
Max W SungTisch Institute at The Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Caly ChienHUTCHMED International Corporation, Florham Park, NJ, USA.
Shivani NandaHUTCHMED International Corporation, Florham Park, NJ, USA.
Christopher TucciHUTCHMED International Corporation, Florham Park, NJ, USA.
Marjo Hahka-KemppinenHUTCHMED International Corporation, Florham Park, NJ, USA.
Andrew Scott PaulsonBaylor Sammons Cancer Center, Dallas, TX, USA.
Sarah Cannon · USCity of Hope · USHealthONE · USIcahn School of Medicine at Mount Sinai · USTexas Oncology · USThe University of Texas MD Anderson Cancer Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Surufatinib, is a potent inhibitor of vascular endothelial growth factor receptors 1-3; fibroblast growth factor receptor-1; colony-stimulating factor 1 receptor. This Phase 1/1b escalation/expansion study in US patients with solid tumors evaluated 5 once daily (QD) surufatinib doses (3 + 3 design) to identify maximum tolerated dose (MTD), recommended Phase 2 dose (RP2D), and evaluate safety and efficacy at the RP2D in 4 disease-specific expansion cohorts including pancreatic neuroendocrine tumors [pNET] and extrapancreatic NETs [epNET]. MTD and RP2D were 300 mg QD (escalation [n = 35]); 5 patients (15.6%) (Dose Limiting Toxicity [DLT] Evaluable Set [n = 32]) had DLTs. Pharmacokinetics were dose proportional. Estimated progression-free survival (PFS) rates at 11 months were 57.4% (95% confidence interval [CI]: 28.7, 78.2) and 51.1% (95% CI: 12.8, 80.3) for pNET and epNET expansion cohorts, respectively. Median PFS was 15.2 (95% CI: 5.2, not evaluable) and 11.5 (95% CI: 6.5,11.5) months. Response rates were 18.8% and 6.3%. The most frequent treatment-emergent adverse events (both cohorts) were fatigue (46.9%), hypertension (43.8%), proteinuria (37.5%), diarrhea (34.4%). Pharmacokinetics, safety, and antitumor efficacy of 300 mg QD oral surufatinib in US patients with pNETs and epNETs are consistent with previously reported studies in China and may support applicability of earlier surufatinib studies in US patients. Clinical trial registration: Clinicaltrials.gov NCT02549937.

Indexed as

NeoplasmsNeuroectodermal Tumors, PrimitiveNeuroendocrine TumorsHumansIndolesMaximum Tolerated DoseProtein Kinase InhibitorsPyrimidinesSulfonamidesTyrosine Kinase InhibitorsVascular Endothelial Growth Factor AVascular Endothelial Growth Factor Receptor-1IndolesProtein Kinase InhibitorsPyrimidinesSulfonamidessurufatinibTyrosine Kinase InhibitorsVascular Endothelial Growth Factor AVascular Endothelial Growth Factor Receptor-1Extrapancreatic neuroendocrine tumorsPancreatic neuroendocrine tumorsSurufatinibVascular endothelial growth factor receptor

Identifiers

PMID37074571
PMCPMC10289989
OpenAlexW4366352303

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.